Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443820 in Multiple Sclerosis
CTR20222933Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oditrasertib in multiple sclerosis (MS), sponsored by Sanofi. Started Nov 2022; status: terminated.
02
Drugs
oditrasertib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on CTR20222933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222933.